 |
 |
 |
| |
|
COPD Intitute > Management Tools > Appendices > Authors > Refs 51-100
References 51 - 100
|
Refs 1 - 50 |
Refs 51 - 100 |
Refs 101 - 150 |
Refs 151 - 200 |
Refs 201 - 250 |
Refs 251 - 291 |
Note:
[return to text]
- goes to the last page in
viewed in COPD-X regardless
of reference number.
|
51
|
Lee, T.A.,
et al., Risk for death associated with
medications for recently diagnosed chronic obstructive pulmonary
disease. Ann Intern Med, 2008. 149(6):
p. 380-90. |
|
52
|
Singh, S.,
Y.K. Loke, and C.D. Furberg, Inhaled
anticholinergics and risk of major adverse cardiovascular events in
patients with chronic obstructive pulmonary disease: a systematic
review and meta-analysis. Jama, 2008.
300(12): p. 1439-50. |
|
53
|
Barr, R.G.,
et al., Tiotropium for stable chronic
obstructive pulmonary disease: A meta-analysis. Thorax, 2006.
61(10): p. 854-62. |
|
54
|
Barr, R.G.,
et al., Tiotropium for stable chronic
obstructive pulmonary disease. Cochrane Database Syst Rev,
2005(2): p. CD002876. |
|
55
|
Kesten, S.,
et al., Pooled clinical trial analysis
of tiotropium safety. Chest, 2006.
130(6): p. 1695-703. |
|
56
|
Tashkin,
D.P., et al., A 4-year trial of
tiotropium in chronic obstructive pulmonary disease. N Engl J
Med, 2008. 359(15): p. 1543-54. |
|
57
|
Appleton,
S., et al., Long-acting beta2-agonists
for poorly reversible chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, 2006. 3:
p. CD001104. |
|
58
|
Molfino,
N.A. and P. Zhang, A meta-analysis on
the efficacy of oral theophylline in patients with stable COPD.
Int J Chron Obstruct Pulmon Dis, 2006.
1(3): p. 261-6. |
|
59
|
Chrystyn,
H., B.A. Mulley, and M.D. Peake, Dose
response relation to oral theophylline in severe chronic obstructive
airways disease. BMJ, 1988. 297(6662):
p. 1506-10. |
|
60
|
Ram, F.S.,
et al., Oral theophylline for chronic
obstructive pulmonary disease. Cochrane Database Syst Rev,
2002(4): p. CD003902. |
|
61
|
Murciano,
D., et al., A randomized, controlled
trial of theophylline in patients with severe chronic obstructive
pulmonary disease. N Engl J Med, 1989.
320(23): p. 1521-5. |
|
62
|
McKay, S.E.,
et al., Value of theophylline
treatment in patients handicapped by chronic obstructive lung
disease. Thorax, 1993. 48(3):
p. 227-32. |
|
63
|
Taylor,
D.R., et al., The efficacy of orally
administered theophylline, inhaled salbutamol, and a combination of
the two as chronic therapy in the management of chronic bronchitis
with reversible air-flow obstruction. Am Rev Respir Dis, 1985.
131(5): p. 747-51. |
|
64
|
Aubier, M.,
Pharmacotherapy of respiratory
muscles. Clin Chest Med, 1988. 9(2):
p. 311-24. |
|
65
|
Moxham, J.,
Aminophylline and the respiratory
muscles: an alternative view. Clin Chest Med, 1988.
9(2): p. 325-36. |
|
66
|
Barnes,
P.J., Theophylline: new perspectives
for an old drug. Am J Respir Crit Care Med, 2003.
167(6): p. 813-8. |
|
67
|
Kobayashi,
M., et al., Effect of low-dose
theophylline on airway inflammation in COPD. Respirology, 2004.
9(2): p. 249-54. |
|
68
|
Zhou, Y., et
al., Positive benefits of theophylline
in a randomized, double-blind, parallel-group, placebo-controlled
study of low-dose, slow-release theophylline in the treatment of
COPD for 1 year. Respirology, 2006.
11(5): p. 603-10. |
|
69
|
MIMS
Australia Pty Ltd.
MIMS Online.
2008 [cited;
Available from:
http://www.mims.com.au/. |
|
70
|
Rennard,
S.I., et al., Cilomilast for COPD:
results of a 6-month, placebo-controlled study of a potent,
selective inhibitor of phosphodiesterase 4. Chest, 2006.
129(1): p. 56-66. |
|
71
|
Rabe, K.F.,
et al., Roflumilast-an oral
anti-inflammatory treatment for chronic obstructive pulmonary
disease: a randomised controlled trial. Lancet, 2005.
366(9485): p. 563-71. |
|
72
|
Postma,
D.S., et al., Moderately severe
chronic airflow obstruction. Can corticosteroids slow down
obstruction? Eur Respir J, 1988. 1(1):
p. 22-6. |
|
73
|
Postma,
D.S., et al., Severe chronic airflow
obstruction: can corticosteroids slow down progression? Eur J
Respir Dis, 1985. 67(1): p. 56-64. |
|
74
|
Decramer,
M., V. de Bock, and R. Dom, Functional
and histologic picture of steroid-induced myopathy in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med, 1996.
153(6 Pt 1): p. 1958-64. |
|
75
|
Decramer,
M., et al., Corticosteroids contribute
to muscle weakness in chronic airflow obstruction. Am J Respir
Crit Care Med, 1994. 150(1): p.
11-6.
[return to text]
|
|
76
|
Decramer, M.
and K.J. Stas, Corticosteroid-induced
myopathy involving respiratory muscles in patients with chronic
obstructive pulmonary disease or asthma. Am Rev Respir Dis,
1992. 146(3): p. 800-2. |
|
77
|
Senderovitz,
T., et al., Steroid reversibility test
followed by inhaled budesonide or placebo in outpatients with stable
chronic obstructive pulmonary disease. The Danish Society of
Respiratory Medicine. Respir Med, 1999.
93(10): p. 715-8. |
|
78
|
Vestbo, J.,
et al., Long-term effect of inhaled
budesonide in mild and moderate chronic obstructive pulmonary
disease: a randomised controlled trial. Lancet, 1999.
353(9167): p. 1819-23. |
|
79
|
Miravitlles,
M., et al., Effect of exacerbations on
quality of life in patients with chronic obstructive pulmonary
disease: a 2 year follow up study. Thorax, 2004.
59(5): p. 387-95. |
|
80
|
Yang, I.A.,
et al., Inhaled corticosteroids for
stable chronic obstructive pulmonary disease. Cochrane Database
Syst Rev, 2007(2): p. CD002991. |
|
81
|
Calverley,
P.M., et al., Salmeterol and
fluticasone propionate and survival in chronic obstructive pulmonary
disease. N Engl J Med, 2007. 356(8):
p. 775-89. |
|
82
|
Pauwels,
R.A., et al., Long-term treatment with
inhaled budesonide in persons with mild chronic obstructive
pulmonary disease who continue smoking. European Respiratory Society
Study on Chronic Obstructive Pulmonary Disease. N Engl J Med,
1999. 340(25): p. 1948-53. |
|
83
|
Wouters,
E.F., et al., Withdrawal of
fluticasone propionate from combined salmeterol/fluticasone
treatment in patients with COPD causes immediate and sustained
disease deterioration: a randomised controlled trial. Thorax,
2005. 60(6): p. 480-7. |
|
84
|
Nannini, L.,
et al., Combined corticosteroid and
long acting beta-agonist in one inhaler for chronic obstructive
pulmonary disease. Cochrane Database Syst Rev, 2004(3): p.
CD003794. |
|
85
|
Kardos, P.,
et al., Impact of
salmeterol/fluticasone propionate versus salmeterol on exacerbations
in severe chronic obstructive pulmonary disease. Am J Respir
Crit Care Med, 2007. 175(2): p.
144-9. |
|
86
|
Ernst, P.,
et al., Inhaled corticosteroid use in
chronic obstructive pulmonary disease and the risk of
hospitalization for pneumonia. Am J Respir Crit Care Med, 2007.
176(2): p. 162-6. |
|
87
|
Wedzicha,
J.A., et al., The prevention of
chronic obstructive pulmonary disease exacerbations by
salmeterol/fluticasone propionate or tiotropium bromide. Am J
Respir Crit Care Med, 2008. 177(1):
p. 19-26. |
|
88
|
Aaron, S.D.,
et al., Tiotropium in combination with
placebo, salmeterol, or fluticasone-salmeterol for treatment of
chronic obstructive pulmonary disease: a randomized trial. Ann
Intern Med, 2007. 146(8): p.
545-55. |
|
89
|
NHS Centre
for Reviews and Dissemination, Inhaler
devices for the management of asthma and COPD. Effective
Healthcare: Bulletin on the Effectiveness of Health Service
Interventions for Decision Makers, 2003.
8(1): p. 1-12. |
|
90
|
Pitta, F.,
et al., Characteristics of physical
activities in daily life in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 2005. 171(9):
p. 972-7. |
|
91
|
Garcia-Aymerich, J., et al., Regular
physical activity reduces hospital admission and mortality in
chronic obstructive pulmonary disease: a population based cohort
study. Thorax, 2006. 61(9): p.
772-8. |
|
92
|
Nici, L., et
al., American Thoracic
Society/European Respiratory Society statement on pulmonary
rehabilitation. Am J Respir Crit Care Med, 2006.
173(12): p. 1390-413. |
|
93
|
Ries, A.L.,
et al., Pulmonary Rehabilitation:
Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines.
Chest, 2007. 131(5 Suppl): p.
4S-42S. |
|
94
|
Lacasse, Y.,
et al., Pulmonary rehabilitation for
chronic obstructive pulmonary disease. Cochrane Database Syst
Rev, 2006(4): p. CD003793. |
|
95
|
Chavannes,
N., et al., Effects of physical
activity in mild to moderate COPD: a systematic review. Br J Gen
Pract, 2002. 52(480): p. 574-8. |
|
96
|
Lotters, F.,
et al., Effects of controlled
inspiratory muscle training in patients with COPD: a meta-analysis.
Eur Respir J, 2002. 20(3): p.
570-6. |
|
97
|
Geddes,
E.L., et al., Inspiratory muscle
training in adults with chronic obstructive pulmonary disease: a
systematic review. Respir Med, 2005.
99(11): p. 1440-58. |
|
98
|
Crowe, J.,
et al., Inspiratory muscle training
compared with other rehabilitation interventions in adults with
chronic obstructive pulmonary disease: a systematic literature
review and meta-analysis. COPD: Journal of Chronic Obstructive
Pulmonary Disease, 2005. 2(3): p.
319-29. |
|
99
|
Brooks, D.,
et al., The effect of
postrehabilitation programmes among individuals with chronic
obstructive pulmonary disease. Eur Respir J, 2002.
20(1): p. 20-9. |
|
100
|
Blackstock,
F. and K. Webster, Disease-specific
health education for COPD: a systematic review of changes in health
outcomes. Health Educ Res, 2007.
22(5): p. 703-17.
[return to text]
|
|

|
Content last updated: |
April 2009 |
|
Page
last updated: |
April 14, 2009 |
|
 |
|
|
|
 |
 |
 |
|